As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

In 2025 EMA recommends 104 new medicines for marketing approval; 38 had a new active substance: Amsterdam, The Netherlands Monday, January 19, 2026, 11:00 Hrs [IST] The European M ...

Edoardo Bove is set to resume his career in England after signing a multi-year contract with Watford, following the mutual ...

US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

The definition is tricky, but the effects of poor metabolic health are clear — and can wreak havoc on the body.

The SFDA is the first regulatory authority globally to grant conditional approval for this medication for the treatment of NSCLC ...

Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025 net product revenue of approximately $182 million and $594 ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...